Interestingly, FH autoantibodies found in patients with non-small cell lung cancer recognize the peptide PIDNGDIT in FH SCR19, inhibit FH binding to lung carcinoma cells and cause increased C3-deposition when binding to FH that is already bound to the cancer cell surface (46). Here, C3 is linked to cancer.